BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12718905)

  • 21. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; FamĂ  R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
    Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
    Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
    Chuah MK; VandenDriessche T; Morgan RA
    Hum Gene Ther; 1995 Nov; 6(11):1363-77. PubMed ID: 8573610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector.
    Jeon HJ; Oh TK; Kim OH; Kim ST
    Yonsei Med J; 2010 Jan; 51(1):52-7. PubMed ID: 20046514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice.
    Milani M; Canepari C; Assanelli S; Merlin S; Borroni E; Starinieri F; Biffi M; Russo F; Fabiano A; Zambroni D; Annoni A; Naldini L; Follenzi A; Cantore A
    EMBO Mol Med; 2024 Jun; 16(6):1427-1450. PubMed ID: 38684862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
    Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
    Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
    Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
    Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.